17β-Estradiol as a Neuroprotective Agent by Prokai-Tatrai, Katalin & Prokai, Laszlo
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
17β-Estradiol as a Neuroprotective Agent
Katalin Prokai-Tatrai and Laszlo Prokai
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.72682
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
17
Katalin Prokai-Tatrai and Laszlo Prokai
Additional information is available at the end of the chapter
Abstract
The pathophysiology of neurodegeneration in the central nervous system is complex 
and multifactorial in nature and yet to be fully understood. Broad-spectrum neuro-
protective agents with multiple mechanisms of action rather than a single druggable 
target are, therefore, highly desirable. The main human estrogen, 17β-estradiol, can 
also be considered a neurosteroid as it forms de novo in the central nervous system, 
and it possesses beneficial effects against practically all critical contributors to neu-
rodegeneration to collectively thwart both the initiation and the progression of neu-
ronal cell death. This chapter details the main aspects of the hormone’s genomic and 
non-genomic actions important to protect the highly vulnerably neurons of the central 
nervous system, as well as translational efforts to successfully realize its powerful neu-
roprotective potential in clinical setting while ensuring both therapeutic safety and 
efficacy.
Keywords: antioxidant, brain, bioprecursor prodrug, broad-spectrum neuroprotectant, 
brain-selective estrogen therapy, cell death, 10β,17β-dihydroxyestra-1,4-dien-3-one 
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1. Introduction
The steroid hormone 17β-estradiol (E2, Figure 1) is the main human estrogen that is not only 
involved in sexual maturation and reproduction but also has a myriad of important roles 
throughout the body affecting, for example, the cardiovascular system, lipid metabolism and 
brain health [1–4]. Therefore, E2 cannot only be considered as just a “female hormone.” In 
humans, the other two endogenously formed estrogens are estrone (E1, Figure 1) and the 
lesser-known estriol (E3, Figure 1) that is the 16-hydroxy derivate of E2 and formed mostly 
during gestation by the placenta. E1 becomes the predominant estrogen in women after 
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menopause, when it is synthesized largely in subcutaneous fat from androstenedione. The 
unique structure of estrogens among steroids arises from the presence of the aromatic A-ring 
(Figure 1).
E2 is now also considered as one of the neurosteroids, as its regioselective local formation in 
the brain has been established [5–8]. Indeed, with today’s modern analytical instrumentations 
and using validated bioassays that are devoid of the limitations of immunoassays [9], brain 
E2 level even in ovariectomized animals (i.e., in animals without gonadal E2 source) can be 
measured [10, 11]. It has been hypothesized that this de novo central formation of E2 due to the 
lack of gonadal E2 sources, for example, as in case of ovariectomy, is essentially a compensa-
tory mechanism to protect the estrogen-deprived brain that cannot receive the hormone from 
the circulation any more, although plasma estrogen levels do not directly correlate with that 
of brain [12, 13]. Additionally, de novo synthesis of E2 with a presumed role of neuroprotection 
in the developing mammalian brain has also been shown [14].
Independent of the loci of estrogen’s gonadal or extra-gonadal biosynthesis from cholesterol 
via a number of enzyme-catalyzed steps, the final process is the oxidation of the 10-methyl 
group of testosterone, followed by elimination and subsequent aromatization into E2 by aro-
matase. This step is the one that has been controlled by aromatase inhibitors in clinical prac-
tice to prevent the reoccurrence of estrogen-dependent malignancies [15].
Among estrogens and estrogenic compounds, E2 also is the best-known estrogen to be used 
as a powerful neuroprotective agent in various in vitro and preclinical animal models of 
neurodegeneration impacting the central nervous system (CNS) [16–20]. It is important to 
emphasize, though, that E2 has a large array of other beneficial effects in the CNS, including 
regulating body temperature, enhancing cognition and memory and ameliorating neuropsy-
chiatric conditions in both females and males [7, 11, 21–23]. While the brain is undoubtedly 
the most frequently studied part of the CNS in the context of neuroprotection [24–26], the 
utility of E2 in protecting the eye (retina and optic nerve) [27–29] and spinal cord [30–32] have 
also been explored with promising outcomes.
Altogether, extensive basic science investigations brought about convincing data on the pleth-
ora of mechanisms by which E2 promotes neuronal survival and protects neurons against a 
wide variety of stressors addressing, thereby, practically all proposed critical contributors 
to neurodegeneration such as inflammation, oxidative stress, excitotoxicity and collapse of 
mitochondrial membrane potential. Clinical and epidemiological observations also suggest 
that in humans the better outcome after neurotrauma (e.g., traumatic brain and spinal cord 
injuries) in premenopausal females compared with age-matched men, at least in part, is due 
to the protective role of endogenous estrogens against neuronal injuries [33, 34].
Figure 1. Chemical structure of human estrogens: estrone (E1), 17β-estradiol (E2) and estriol (E3).
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2. Mechanistic overview of neuroprotection by estrogens
The broad-spectrum protective mechanism of E2 on injured neurons is the end result of well-
orchestrated and synergistic combination of genomic and non-genomic actions of the hor-
mone that allows for prevention of both the initiation and progression of neuronal cell death. 
This implicates a significant translational value for the hormone upon restricting its action to 
the CNS, as detailed in the following section.
2.1. Genomic pathways in E2 neuroprotection
Estrogen receptors (ERs) are expressed throughout the brain [35, 36] indicating their role in 
various CNS functions including neuroprotection. ER density is higher in the hypothala-
mus than in extrahypothalamic areas with overlapping expression of the two isoforms ERα 
and ERβ [35, 36]. In some brain regions, ERα or ERβ may also be co-localized in cells [37]. 
However, ERβ is highly expressed in the cortex [38] and hippocampus [39, 40]. Consequently, 
estrogen impacts the function of extrahypothalamic areas that are not involved in sex matura-
tion and reproduction [41].
The two ERs have similar affinities to endogenous estrogens [42]. Just like many other mem-
bers of the nuclear receptor superfamily of proteins, they elicit their genomic effect through 
gene transcription [43]. The sequence of the classical ligand-dependent genomic mechanism of 
estrogens’ neuroprotective action is summarized in Figure 2. After E2 (or in general, an estro-
gen) distributes into the neuron and reaches the nucleus, it is ligated to its cognate receptor. The 
ligated ERs form homo- (ERα/ERα or ERβ/ERβ) or heterodimers (ERα/ERβ) that bind to the 
estrogen-response element (ERE) of the nuclear DNA. Transcriptional activation is enabled by 
Figure 2. A simplified model for the ligand-dependent genomic mechanism of E2 neuroprotection. After E2 distributes 
into the neuron (A) and enters the nucleus, it binds to the cognate receptor followed by dimerization of the ligated ER 
that binds, together with co-regulators, to the nuclear DNA’s ERE, which results in the transcription of the corresponding 
gene (B). E2, ER, co-regulator (Co-r) and the nuclear DNA are symbolized by the filled steroid shape, rounded rectangles 
and elongated rectangle showing an ERE (shaded area), respectively.
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a constitutively active and a ligand-dependent function located at the amino-terminus and in 
the carboxy-terminal ligand-binding domain of ERs, respectively [44]. The DNA-bound dimers 
recruit co-regulator proteins [45], which can participate in and also recruit many enzymatic 
and structural proteins permitting the modulation of chromatin structure to facilitate or block 
gene expression [46]. Additionally, ERE-independent mechanisms have also been shown [47].
Neuroprotective target genes for E2 that directly support vital neuronal functions include neu-
rotrophic factors such as the brain-derived neurotrophic factor [48]. Additional target genes are 
involved in apoptosis to remove unneeded, damaged or potentially deleterious cells [49] play-
ing thereby a central role in development and homeostasis. Through the apoptosis-associated 
genomic mechanism, E2 has been shown to rescue neurons through the induction of anti-apop-
totic proteins such as Bcl-2 [50] or suppression of apoptotic proteins such as the Bcl-2-associated 
X protein [50, 51]. Induction of several gene products that maintain cellular architecture such as 
neurofilament, tau and microtubulin-associated proteins and many additional genomic path-
ways potentially associated with E2’s neuroprotection have also been described [52].
2.2. Modulation of intracellular signaling by E2
E2 also rapidly induces numerous cellular responses, which cannot be explained by a delayed 
genomic effect. ERs have been shown to be present in membrane compartments and in the 
cytoplasm [53, 54]. Specifically, ERα and ERβ are also found as homo or heterodimers at the 
cell membrane; they are membrane-associated but not actually embedded in the membrane. 
In addition, a G protein-coupled estrogen receptor (GPER) is localized mainly to intracellular 
membranes, including the endoplasmic reticulum and Golgi apparatus, under steady-state 
conditions [55]. G protein-coupled receptors such as GPER can actually signal from intracel-
lular locations [56] and activation results in intracellular Ca2+-mobilization and synthesis of 
phosphatidylinositol 3,4,5-triphosphate in the nucleus, which could impact gene transcrip-
tion indirectly. The mitogen-activated protein kinase (MAPK) cascade [57] and the cyclic-
AMP-responsive element-binding protein signaling pathway [58, 59] also respond rapidly to 
E2 and have been implicated in its neuroprotective effects.
An E2-ER complex can also function through cytoplasmic signaling to provide neuroprotec-
tion [60]. For example, ERs have been shown to bind in a ligand-dependent manner to the p85 
alpha regulatory subunit of phosphatidylinositol 3-kinase (PI3K) [61, 62]. Therefore, stimula-
tion with E2 increases ER-associated PI3K activity, leading to the activation of protein kinase 
B/Akt and endothelial nitric oxide synthase. However, modulation of intracellular pathways 
may occur though the binding of E2 to ERs, or independently of ligand binding [63, 64]. A 
representative of the non-genomic mechanism involving the modulation of intracellular sig-
naling through ERs is summarized schematically in Figure 3.
E2 has been proposed to influence neurotransmission directly by binding to various trans-
membrane ion channels [65, 66]. Localization of ERβ to the mitochondria has also been shown 
[67], implicating E2 in the regulation of mitochondrial structure and function in the brain [68]. 
In addition to estrogen potentially influencing bioenergetics through long-lasting nuclear-
associated processes, rapid mitochondria-intrinsic signaling mechanisms that promote the 
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maintenance of this organelle’s integrity could contribute therefore to the neuroprotective action 
of E2. Essentially, the hormone could minimize mitochondrial dysfunctions, which accom-
pany neurotrauma, aging and neurodegenerative diseases [69]. However, continued research 
is needed to fully understand molecular details about the apparently complex interactions 
between ERs and cellular signaling pathways in the context of neuroprotective mechanisms.
2.3. Anti-inflammatory action
The influence of E2 on neuroinflammation, a process commonly accompanying neurotrauma 
and neurodegenerative diseases [70–72], has been well established. Direct action on microglia 
and astrocytes (the cellular component of the neuroimmune system) and response to periph-
eral blood cells’ infiltration to the brain have been implicated as major contributors to the 
observed anti-inflammatory action of the hormone often impacting the cerebral vasculature 
[73, 74]. For example, E2 can suppress chemokine-mediated induction of the cyclooxygen-
ase-2 (COX-2) pathway in cerebral blood vessels thereby preventing migration of microglia 
into the brain after an inflammatory challenge [75]. Although inflammatory processes in the 
brain are usually associated with microglia and astrocytes, expression of the COX-2 gene in 
neurons and possible mechanisms by which E2 down-regulates this inflammation-associated 
gene have been shown recently [76]. Specifically, ERβ contributes to neuronal expression of 
COX-2, and E2 leads to increased recruitment of histone deacetylase 1 (HDAC1), switch-inde-
pendent 3A (Sin3A) and a concomitant reduction of nuclear factor-κ B (NF-κ B) p65 occupancy 
and histone 4 acetylation levels. The hormone also prevents the activation of microglia and 
the recruitment of peripheral monocytes induced by a toxic stimulus. This effect involves ERα 
activation and reduces the expression of pro-inflammatory mediators and E2 have also shown 
to prevent morphological changes occurring in microglia during inflammatory response [77]. 
Decrease of microglial superoxide production and phagocytic activity by both an ER- and 
Figure 3. An example of non-genomic action of E2 involving interaction with intracellular signaling pathways through 
ERs. As in Figure 2, E2, ER and the nuclear DNA are represented by the filled steroid shapes, rounded rectangles and 
elongated rectangle indicating a regulated gene promoter (shaded area), respectively, while the ER-interacting protein 
(↔) such as PI3K is shown by a shaded oval.
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MAPK-dependent pathway have also been reported among the anti-inflammatory effects of 
E2 [78]. In addition, the hormone inhibits pro-inflammatory gene expression by controlling 
intracellular localization of NF-κ B [79].
2.4. Antioxidant effects
Oxidative stress-induced damage has been linked to brain aging [80], neurodegenerative 
diseases [81] and neurotrauma [25, 26]. From a long time, therapeutic antioxidant interven-
tions have been proposed to reduce the detrimental impact of oxidative stress [82]. E2’s 
ER-independent antioxidant effects are mainly due to its ability to attenuate free-radical 
reactions [83], although indirect mechanisms such as up regulation of antioxidant enzymes 
[84, 85] and chelation of redox-active metal ions [86] have been reported. The neuroprotective 
effect of the hormone through direct oxidative stress reduction has been recognized in part 
by structure-activity relationship studies [87–89]. Acute E2 neuroprotection in ischemic brain 
[90] or against damage by ionizing radiation [91] may be largely conferred through antioxi-
dant mechanisms.
The quintessential feature of estrogens as neuroprotective antioxidants is their phenolic 
A-ring [83, 92, 93]. Because of its lipophilicity, E2 concentrates in lipid-rich regions of the cell 
such as cellular membranes [94]. Therefore, it is likely that estrogens act in vivo as a highly 
localized antioxidant [83]. The mechanism of direct oxyradical-scavenging by E2 functioning 
as a phenolic antioxidant is shown schematically in Figure 4.
The process involves H-atom transfer that causes an interruption of free-radical chain reac-
tions, such as lipid peroxidation (R = LOO, where L represents a lipid). Estrogens, indeed, 
reduce lipid peroxidation in cells and tissues of the CNS [95]. However, the chain-breaking 
reaction leaves behind a radical product (phenoxyl radical) whose fate has to be explained in 
consideration of an efficient antioxidant action observed both in vitro and in vivo. Indeed, phe-
nolic antioxidants can be regenerated from the corresponding phenoxyl radicals by a reaction 
with ascorbic acid (vitamin C) [96] or through glutathione-dependent free-radical reductase 
[97]; therefore, a continuous antioxidant cycle is established by E2.
Figure 4. E2’s effect through the classical phenolic antioxidant mechanism. The solid arrows represent the chain-
breaking H-atom transfer, such as lipid peroxidation, while the dashed arrows indicate the conversion of the E2-derived 
phenoxyl radical back to the phenolic compound by an endogenous reductant (AH) such as ascorbic acid or glutathione.
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Our laboratory pioneered in recognizing a complementary novel neuroprotective antioxidant 
cycle that involves a para-quinol as a molecular intermediate of oxyradical scavenging and, then, 
NADPH-mediated enzyme-catalyzed reductive aromatization [98–100] to regenerate E2, as 
shown in Figure 5. We wish to name this previously unrecognized antioxidant cycle for simple 
phenolic antioxidants as the “Prokai antioxidant cycle.” The enzyme activity driving the reduc-
tive phase of the cycle is observed predominantly in neuronal tissue [101]. Beyond its mechanis-
tic significance regarding oxidative stress-reducing effect, this discovery has prompted a strategy 
for brain-selective estrogen therapy using a prodrug approach detailed in the following section.
3. CNS-selective estrogen neurotherapy
The pathophysiology of neurodegeneration in the central nervous system is complex and mul-
tifactorial in nature [102]. Therefore, it is not surprising that an agent like E2 can provide robust 
protection against a myriad of neuronal insults owing to its broad-spectrum activity resulting 
from well-orchestrated genomic and non-genomic actions, as detailed in Section 2. The need 
for clinical therapeutic interventions that can be used to target multiple parallel mechanisms 
of neuronal injury has been repeatedly expressed [101–103]. We argue that, despite profound 
dichotomy between basic science and clinical studies, E2 is ideally suited to be developed as a 
broad-spectrum neuroprotectant if its action can be restricted to the CNS, that is, to the site of 
action to avoid undesirable peripheral hormonal burdens. Since neurotrauma triggers a cas-
cade of biochemical events leading to further damages decreasing thereby the chance of appre-
ciable functional recovery [17, 20, 102, 103], chronic pharmacotherapeutic interventions should 
be considered in the context of translational research. This, on the other hand, brings about crit-
ical considerations for safety and efficacy, which highlights the need for brain-selective (or in 
general CNS-selective) neurotherapy, considering both a preventative and a curative modality.
When estrogen neurotherapy is considered, however, one cannot ignore the (in)famous 
Women’s Health Initiative (WHI) study [104]. This was a placebo-controlled, randomized 
trial of hormone “replacement” therapy in postmenopausal women that indicated detrimen-
tal consequences of estrogen and progesterone supplementations, among others, for brain 
Figure 5. The Prokai antioxidant cycle for E2 through the formation of a para-quinol (10β,17β-dihydroxyestra-1,4-dien-
3-one, DHED) as an intermediate, which is reduced to the parent hormone by enzyme-catalyzed reduction involving 
NADPH as cofactor.
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health, propagating thereby a dogma that all estrogens (and progestins) are “created equal.” 
The fact is that WHI did not use human hormones and, thus, did not study the effect of 
hormone replacement per se in aging women. On the contrary, conjugated equine estrogens 
(CEE) and a synthetic progestin were used for women with intact uterus. CEE is a complex 
mixture of over 60 different estrogens from pregnant mares’ urine, and it only contains a small 
amount of E2: the main constituents are the sulfate esters of B-ring saturated and unsaturated 
estrogens [105]. The pharmacokinetic and toxicology profiles of these non-human estrogens 
are different from those of E2; therefore, direct comparison between E2 and CEE is fundamen-
tally unjustified [106, 107]. Accordingly, the beneficial central effects of E2, including robust 
neuroprotection based on clinical, epidemiological and basic science observations should not 
be undermined in view of the confusion brought about by the WHI studies.
Nevertheless, an E2-based neurotherapy cannot be realized in clinical settings until E2’s actions 
are restricted to the site of action assuring therapeutic safety and efficacy. Currently approved 
E2 dosage forms expose the entire body to the hormone through the circulation, potentially 
leading to detrimental side-effects including cardiovascular problems and the development of 
certain type of cancers upon chronic administration that is required for long-term neuropro-
tection and functional recovery after neurotrauma. Feminization (e.g., gynecomastia) is also a 
critical negative aspect of estrogen therapy, especially in case of children and males.
Early attempts to restrict E2’s actions to the brain upon systemic administration included the 
so-called chemical delivery system, which was conceptually a complex prodrug approach 
carrying a 1,4-dihydrotrigonellyl promoiety and is capable to usher the hormone through the 
blood brain barrier (BBB). Once in the brain, the prodrug is oxidized analogously to that of 
NADP(H) ⇌ NADP+, locking thereby the oxidized prodrug into the brain before it releases 
E2 [108]. This approach does result in significantly increased brain-enhanced delivery of the 
hormone compared to that of simple prodrugs of E2; however, it still results in sufficient 
increase in circulating E2 that can produce unwanted peripheral hormonal burdens [10, 109]. 
Prodrugs are inert precursors of their corresponding biologically active parent drugs and they 
traditionally carry auxiliary bioreversible “promoiety(ies)” that are removed enzymatically 
(rarely via chemical reaction, such as pH-dependent hydrolysis) in the body [108].
An important development in achieving a true CNS-selective estrogen therapy has been 
achieved by our laboratory [101] and was derived from our previous discovery of a novel 
antioxidant cycle for estrogens we call the Prokai antioxidant cycle for simple phenolic anti-
oxidants [98–100], and detailed in Section 2. We recognized that 10β,17β-dihydroxyestra-1,4-
dien-3-one (DHED, Figures 5 and 6), which is chemically a para-quinol (not to be mistaken 
for quinones involved in E2-induced carcinogenesis through redox cycling [99]), can be 
reductively rearomatized to the parent E2 and, thus, could serve as a bioprecursor prodrug 
for E2. The lesser-known bioprecursor prodrugs do not carry auxiliary promoiety(ies) [108] 
because the bioreversible chemical manipulation is carried out within the drug molecule itself 
[101, 110]. Therefore, creation of bioprecursor prodrugs, such as DHED, requires significantly 
greater innovation than that of simple prodrugs; moreover, potential toxicity issues that may 
arise from the release of the “promoity(ies)” from simple prodrugs is eliminated with bio-
precursor prodrugs. Indeed, we have established that CNS-specific and NADPH-dependent 
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dehydrogenase/reductase metabolized DHED to E2 (Figure 6), while prodrug activation did 
not occur in the periphery. This is an unprecedented and distinguishing feature of DHED 
in the context of translational research [101]. With a series of in vitro and in vivo studies, we 
showed that with DHED, for the first time, E2’s actions can be restricted to the brain indepen-
dently of the route and duration of DHED administration and, therefore, it can be used (at 
least in preclinical settings) for the efficacious treatment of estrogen-responsive and centrally 
regulated maladies and injuries, including neurodegeneration brought about by ischemic 
stroke, without hormonal burdens for the rest of the body [101].
The transient middle cerebral artery occlusion (tMCAO) model followed by reperfusion is 
one the most frequently used preclinical animal models for testing an agent for its ability 
to act as a neuroprotectant, that is, to reduce infarct volume and aid in functional recovery 
[20, 24, 101, 111]. As Figure 7 shows, a dose-dependent reduction of infarct volumes and neu-
rological deficits was observed in DHED-treated animals. Moreover, about 10-times higher 
systemic E2 (i.e., the parent drug that is formed in the brain from DHED) dose was needed to 
achieve the same neuroprotection indicating the profound ability of the bioprecursor prodrug 
to enter into the brain from the circulation and, then, produce E2 within the brain, and only in 
Figure 6. Schematic illustration of DHED bioprecursor prodrug’s CNS-selective enzymatic metabolism to E2 via an 
NADPH-dependent reductase.
Figure 7. Dose-dependent (A) brain infarct volumes and (B) neurological deficit (ND) scores in rats treated with DHED 
1 h before tMCAO followed by 24-h reperfusion [101]. The control groups received E2 (200 μg/kg, s.c., approximately 
representing ED50, equivalent to 50% of the maximum effect) or vehicle alone. ©Reproduced with permission by the 
American Association for the Advancement of Science.
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the brain. In the context of translational research, it is noteworthy that the capacity to generate 
E2 from DHED is not lost in an injured brain, as neuroprotection was highly preserved post-
stroke and, again, no hormonal exposure to the rest of the body was observed [101].
4. Conclusion
As neurotrauma and neurodegeneration in the CNS are complex and multifactorial in 
nature requiring therefore broad-spectrum therapeutic interventions, E2 is an attractive 
lead agent to address unmet medical needs in this field. The powerful antioxidant action 
of E2 against oxidative stress owing to its phenolic A-ring is unique among neurosteroids 
with potential neuroprotective roles; therefore, non-genomic mechanisms contribute sig-
nificantly to the overall neuroprotection. This chapter presented an overview of our current 
knowledge on the well-orchestrated genomic and non-genomic events by which E2 could 
beneficially counteract the initiation and/or progression of neuronal cell death. However, 
there has been incongruency between basic science and clinical studies in terms of estrogen 
therapy impacting the brain because most researchers ignore the requirement to confine 
E2’s actions into the CNS upon systemic administration to ensure therapeutic safety and 
efficacy. We highlighted here a novel and unique bioprecursor prodrug approach our labo-
ratory pioneered for brain-selective delivery of E2 without exposing the rest of the body to 
unwanted hormonal burden.
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